Voyager Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 11, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | | |
|---|---|---|---|
| Date: March 11, 2025 | VOYAGER THERAPEUTICS, INC. | ||
| By: | /s/ Alfred Sandrock, M.D., Ph.D. | ||
| | | | Alfred Sandrock, M.D., Ph.D.Chief Executive Officer, President, and Director |
SIGNATURES AND POWER OF ATTORNEY** **
We, the undersigned directors and officers of Voyager Therapeutics, Inc. (the “Company”), hereby severally constitute and appoint Alfred Sandrock and Nate Jorgensen, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, any and all amendments to this Annual Report on Form 10-K, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of us might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.
Pursuant to therequirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed by the following persons in the capacities and on the dates indicated.
| Name | Title | Date | ||
|---|---|---|---|---|
| | | | | |
| /s/ Alfred Sandrock, M.D., Ph.D. | | Chief Executive Officer, President, and Director | | March 11, 2025 |
| Alfred Sandrock, M.D., Ph.D. | | (Principal Executive Officer) | | |
| | | | | |
| /s/ Nathan Jorgensen, Ph.D. | | Chief Financial Officer | | March 11, 2025 |
| Nathan Jorgensen, Ph.D. | | (Principal Financial and Accounting Officer) | | |
| | | | | |
| /s/ Michael Higgins | | Director (Chairman of the Board) | | March 11, 2025 |
| Michael Higgins | | | ||
| | | | | |
| /s/ Grace E. Colón, Ph.D. | | Director | | March 11, 2025 |
| Grace E. Colón, Ph.D. | | | ||
| | | | | |
| /s/ James Geraghty | | Director | | March 11, 2025 |
| James Geraghty | | | ||
| | | | | |
| /s/ Steven Hyman, M.D. | | Director | | March 11, 2025 |
| Steven Hyman, M.D. | | | | |
| | | | | |
| /s/ Catherine J. Mackey, Ph.D. | | Director | | March 11, 2025 |
| Catherine J. Mackey, Ph.D. | | | | |
| | | | | |
| /s/ Jude Onyia, Ph.D. | | Director | | March 11, 2025 |
| Jude Onyia, Ph.D. | | | | |
| | | | | |
| /s/ Glenn Pierce, M.D., Ph.D. | | Director | | March 11, 2025 |
| Glenn Pierce, M.D., Ph.D. | | | | |
| | | | | |
| /s/ George Scangos, Ph.D. | | Director | | March 11, 2025 |
| George Scangos, Ph.D. | | | | |
| | | | | |
| /s/ Nancy Vitale | | Director | | March 11, 2025 |
| Nancy Vitale | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.